Management of oligometastatic prostate cancer
Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Result...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Miszczyk, Marcin [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2023 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Magazine of European Medical Oncology - Wien : Springer, 2008, 17(2023), 1 vom: 18. Dez., Seite 35-39 |
|---|---|
| Übergeordnetes Werk: |
volume:17 ; year:2023 ; number:1 ; day:18 ; month:12 ; pages:35-39 |
| Links: |
|---|
| DOI / URN: |
10.1007/s12254-023-00938-6 |
|---|
| Katalog-ID: |
SPR054667682 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054667682 | ||
| 003 | DE-627 | ||
| 005 | 20240207064624.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12254-023-00938-6 |2 doi | |
| 035 | |a (DE-627)SPR054667682 | ||
| 035 | |a (SPR)s12254-023-00938-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miszczyk, Marcin |e verfasserin |0 (orcid)0000-0002-4375-0827 |4 aut | |
| 245 | 1 | 0 | |a Management of oligometastatic prostate cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 | ||
| 520 | |a Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. | ||
| 650 | 4 | |a Chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hormone therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Radiotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytoreductive prostatectomy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Metastasis-directed therapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Slusarczyk, Aleksander |4 aut | |
| 700 | 1 | |a Quhal, Fahad |4 aut | |
| 700 | 1 | |a Klemm, Jakob |4 aut | |
| 700 | 1 | |a Matsukawa, Akihiro |4 aut | |
| 700 | 1 | |a Przydacz, Mikołaj |4 aut | |
| 700 | 1 | |a Bryniarski, Piotr |4 aut | |
| 700 | 1 | |a Shariat, Shahrokh F. |4 aut | |
| 700 | 1 | |a Rajwa, Paweł |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Magazine of European Medical Oncology |d Wien : Springer, 2008 |g 17(2023), 1 vom: 18. Dez., Seite 35-39 |w (DE-627)568488733 |w (DE-600)2428960-7 |x 1865-5076 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:1 |g day:18 |g month:12 |g pages:35-39 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12254-023-00938-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_171 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_224 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_250 | ||
| 912 | |a GBV_ILN_281 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2050 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2056 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2472 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4328 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 1 |b 18 |c 12 |h 35-39 | ||
| author_variant |
m m mm a s as f q fq j k jk a m am m p mp p b pb s f s sf sfs p r pr |
|---|---|
| matchkey_str |
article:18655076:2023----::aaeetflgmtsaipo |
| hierarchy_sort_str |
2023 |
| publishDate |
2023 |
| allfields |
10.1007/s12254-023-00938-6 doi (DE-627)SPR054667682 (SPR)s12254-023-00938-6-e DE-627 ger DE-627 rakwb eng Miszczyk, Marcin verfasserin (orcid)0000-0002-4375-0827 aut Management of oligometastatic prostate cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. Chemotherapy (dpeaa)DE-He213 Hormone therapy (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Cytoreductive prostatectomy (dpeaa)DE-He213 Metastasis-directed therapy (dpeaa)DE-He213 Slusarczyk, Aleksander aut Quhal, Fahad aut Klemm, Jakob aut Matsukawa, Akihiro aut Przydacz, Mikołaj aut Bryniarski, Piotr aut Shariat, Shahrokh F. aut Rajwa, Paweł aut Enthalten in Magazine of European Medical Oncology Wien : Springer, 2008 17(2023), 1 vom: 18. Dez., Seite 35-39 (DE-627)568488733 (DE-600)2428960-7 1865-5076 nnns volume:17 year:2023 number:1 day:18 month:12 pages:35-39 https://dx.doi.org/10.1007/s12254-023-00938-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 17 2023 1 18 12 35-39 |
| spelling |
10.1007/s12254-023-00938-6 doi (DE-627)SPR054667682 (SPR)s12254-023-00938-6-e DE-627 ger DE-627 rakwb eng Miszczyk, Marcin verfasserin (orcid)0000-0002-4375-0827 aut Management of oligometastatic prostate cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. Chemotherapy (dpeaa)DE-He213 Hormone therapy (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Cytoreductive prostatectomy (dpeaa)DE-He213 Metastasis-directed therapy (dpeaa)DE-He213 Slusarczyk, Aleksander aut Quhal, Fahad aut Klemm, Jakob aut Matsukawa, Akihiro aut Przydacz, Mikołaj aut Bryniarski, Piotr aut Shariat, Shahrokh F. aut Rajwa, Paweł aut Enthalten in Magazine of European Medical Oncology Wien : Springer, 2008 17(2023), 1 vom: 18. Dez., Seite 35-39 (DE-627)568488733 (DE-600)2428960-7 1865-5076 nnns volume:17 year:2023 number:1 day:18 month:12 pages:35-39 https://dx.doi.org/10.1007/s12254-023-00938-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 17 2023 1 18 12 35-39 |
| allfields_unstemmed |
10.1007/s12254-023-00938-6 doi (DE-627)SPR054667682 (SPR)s12254-023-00938-6-e DE-627 ger DE-627 rakwb eng Miszczyk, Marcin verfasserin (orcid)0000-0002-4375-0827 aut Management of oligometastatic prostate cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. Chemotherapy (dpeaa)DE-He213 Hormone therapy (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Cytoreductive prostatectomy (dpeaa)DE-He213 Metastasis-directed therapy (dpeaa)DE-He213 Slusarczyk, Aleksander aut Quhal, Fahad aut Klemm, Jakob aut Matsukawa, Akihiro aut Przydacz, Mikołaj aut Bryniarski, Piotr aut Shariat, Shahrokh F. aut Rajwa, Paweł aut Enthalten in Magazine of European Medical Oncology Wien : Springer, 2008 17(2023), 1 vom: 18. Dez., Seite 35-39 (DE-627)568488733 (DE-600)2428960-7 1865-5076 nnns volume:17 year:2023 number:1 day:18 month:12 pages:35-39 https://dx.doi.org/10.1007/s12254-023-00938-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 17 2023 1 18 12 35-39 |
| allfieldsGer |
10.1007/s12254-023-00938-6 doi (DE-627)SPR054667682 (SPR)s12254-023-00938-6-e DE-627 ger DE-627 rakwb eng Miszczyk, Marcin verfasserin (orcid)0000-0002-4375-0827 aut Management of oligometastatic prostate cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. Chemotherapy (dpeaa)DE-He213 Hormone therapy (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Cytoreductive prostatectomy (dpeaa)DE-He213 Metastasis-directed therapy (dpeaa)DE-He213 Slusarczyk, Aleksander aut Quhal, Fahad aut Klemm, Jakob aut Matsukawa, Akihiro aut Przydacz, Mikołaj aut Bryniarski, Piotr aut Shariat, Shahrokh F. aut Rajwa, Paweł aut Enthalten in Magazine of European Medical Oncology Wien : Springer, 2008 17(2023), 1 vom: 18. Dez., Seite 35-39 (DE-627)568488733 (DE-600)2428960-7 1865-5076 nnns volume:17 year:2023 number:1 day:18 month:12 pages:35-39 https://dx.doi.org/10.1007/s12254-023-00938-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 17 2023 1 18 12 35-39 |
| allfieldsSound |
10.1007/s12254-023-00938-6 doi (DE-627)SPR054667682 (SPR)s12254-023-00938-6-e DE-627 ger DE-627 rakwb eng Miszczyk, Marcin verfasserin (orcid)0000-0002-4375-0827 aut Management of oligometastatic prostate cancer 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. Chemotherapy (dpeaa)DE-He213 Hormone therapy (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Cytoreductive prostatectomy (dpeaa)DE-He213 Metastasis-directed therapy (dpeaa)DE-He213 Slusarczyk, Aleksander aut Quhal, Fahad aut Klemm, Jakob aut Matsukawa, Akihiro aut Przydacz, Mikołaj aut Bryniarski, Piotr aut Shariat, Shahrokh F. aut Rajwa, Paweł aut Enthalten in Magazine of European Medical Oncology Wien : Springer, 2008 17(2023), 1 vom: 18. Dez., Seite 35-39 (DE-627)568488733 (DE-600)2428960-7 1865-5076 nnns volume:17 year:2023 number:1 day:18 month:12 pages:35-39 https://dx.doi.org/10.1007/s12254-023-00938-6 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 17 2023 1 18 12 35-39 |
| language |
English |
| source |
Enthalten in Magazine of European Medical Oncology 17(2023), 1 vom: 18. Dez., Seite 35-39 volume:17 year:2023 number:1 day:18 month:12 pages:35-39 |
| sourceStr |
Enthalten in Magazine of European Medical Oncology 17(2023), 1 vom: 18. Dez., Seite 35-39 volume:17 year:2023 number:1 day:18 month:12 pages:35-39 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Chemotherapy Hormone therapy Radiotherapy Cytoreductive prostatectomy Metastasis-directed therapy |
| isfreeaccess_bool |
false |
| container_title |
Magazine of European Medical Oncology |
| authorswithroles_txt_mv |
Miszczyk, Marcin @@aut@@ Slusarczyk, Aleksander @@aut@@ Quhal, Fahad @@aut@@ Klemm, Jakob @@aut@@ Matsukawa, Akihiro @@aut@@ Przydacz, Mikołaj @@aut@@ Bryniarski, Piotr @@aut@@ Shariat, Shahrokh F. @@aut@@ Rajwa, Paweł @@aut@@ |
| publishDateDaySort_date |
2023-12-18T00:00:00Z |
| hierarchy_top_id |
568488733 |
| id |
SPR054667682 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR054667682</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240207064624.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240207s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12254-023-00938-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR054667682</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12254-023-00938-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Miszczyk, Marcin</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-4375-0827</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Management of oligometastatic prostate cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hormone therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cytoreductive prostatectomy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metastasis-directed therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Slusarczyk, Aleksander</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quhal, Fahad</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klemm, Jakob</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsukawa, Akihiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Przydacz, Mikołaj</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bryniarski, Piotr</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shariat, Shahrokh F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajwa, Paweł</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Magazine of European Medical Oncology</subfield><subfield code="d">Wien : Springer, 2008</subfield><subfield code="g">17(2023), 1 vom: 18. Dez., Seite 35-39</subfield><subfield code="w">(DE-627)568488733</subfield><subfield code="w">(DE-600)2428960-7</subfield><subfield code="x">1865-5076</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:18</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:35-39</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12254-023-00938-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">18</subfield><subfield code="c">12</subfield><subfield code="h">35-39</subfield></datafield></record></collection>
|
| author |
Miszczyk, Marcin |
| spellingShingle |
Miszczyk, Marcin misc Chemotherapy misc Hormone therapy misc Radiotherapy misc Cytoreductive prostatectomy misc Metastasis-directed therapy Management of oligometastatic prostate cancer |
| authorStr |
Miszczyk, Marcin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)568488733 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1865-5076 |
| topic_title |
Management of oligometastatic prostate cancer Chemotherapy (dpeaa)DE-He213 Hormone therapy (dpeaa)DE-He213 Radiotherapy (dpeaa)DE-He213 Cytoreductive prostatectomy (dpeaa)DE-He213 Metastasis-directed therapy (dpeaa)DE-He213 |
| topic |
misc Chemotherapy misc Hormone therapy misc Radiotherapy misc Cytoreductive prostatectomy misc Metastasis-directed therapy |
| topic_unstemmed |
misc Chemotherapy misc Hormone therapy misc Radiotherapy misc Cytoreductive prostatectomy misc Metastasis-directed therapy |
| topic_browse |
misc Chemotherapy misc Hormone therapy misc Radiotherapy misc Cytoreductive prostatectomy misc Metastasis-directed therapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Magazine of European Medical Oncology |
| hierarchy_parent_id |
568488733 |
| hierarchy_top_title |
Magazine of European Medical Oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)568488733 (DE-600)2428960-7 |
| title |
Management of oligometastatic prostate cancer |
| ctrlnum |
(DE-627)SPR054667682 (SPR)s12254-023-00938-6-e |
| title_full |
Management of oligometastatic prostate cancer |
| author_sort |
Miszczyk, Marcin |
| journal |
Magazine of European Medical Oncology |
| journalStr |
Magazine of European Medical Oncology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2023 |
| contenttype_str_mv |
txt |
| container_start_page |
35 |
| author_browse |
Miszczyk, Marcin Slusarczyk, Aleksander Quhal, Fahad Klemm, Jakob Matsukawa, Akihiro Przydacz, Mikołaj Bryniarski, Piotr Shariat, Shahrokh F. Rajwa, Paweł |
| container_volume |
17 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Miszczyk, Marcin |
| doi_str_mv |
10.1007/s12254-023-00938-6 |
| normlink |
(ORCID)0000-0002-4375-0827 |
| normlink_prefix_str_mv |
(orcid)0000-0002-4375-0827 |
| title_sort |
management of oligometastatic prostate cancer |
| title_auth |
Management of oligometastatic prostate cancer |
| abstract |
Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 |
| abstractGer |
Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 |
| abstract_unstemmed |
Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_152 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2118 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
| container_issue |
1 |
| title_short |
Management of oligometastatic prostate cancer |
| url |
https://dx.doi.org/10.1007/s12254-023-00938-6 |
| remote_bool |
true |
| author2 |
Slusarczyk, Aleksander Quhal, Fahad Klemm, Jakob Matsukawa, Akihiro Przydacz, Mikołaj Bryniarski, Piotr Shariat, Shahrokh F. Rajwa, Paweł |
| author2Str |
Slusarczyk, Aleksander Quhal, Fahad Klemm, Jakob Matsukawa, Akihiro Przydacz, Mikołaj Bryniarski, Piotr Shariat, Shahrokh F. Rajwa, Paweł |
| ppnlink |
568488733 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s12254-023-00938-6 |
| up_date |
2024-07-04T02:34:42.415Z |
| _version_ |
1803614140411936768 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR054667682</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240207064624.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240207s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s12254-023-00938-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR054667682</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12254-023-00938-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Miszczyk, Marcin</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-4375-0827</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Management of oligometastatic prostate cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2023</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Purpose This study aimed to review the current management strategies for oligometastatic prostate cancer (omPCa), focusing on their clinical implications. Materials and methods A narrative review method was adopted, synthesizing the leading evidence on issues associated with omPCa management. Results Androgen deprivation therapy (ADT) remains fundamental in omPCa. Combination with androgen receptor signalling inhibitors (ARSI) and/or chemotherapy were found to improve survival. Triplet therapy can be considered a new standard of care; however, no direct comparison with ADT + ARSI doublet exists. There is a trend towards patient-tailored decisions for optimal systemic treatment, mainly based on clinical data such as disease volume. For low-volume omPCa patients, local radiotherapy showed modest survival improvement and should be considered as a part of multimodality treatment. Cytoreductive radical prostatectomy is promising but remains investigational. Metastases-directed therapy (MDT) can be used to delay the initiation of ADT in metachronous omPCa patients. Although promising, insufficient data exist to conclusively prove that MDT benefits major oncologic outcomes in the context of treatment intensification. In scenarios where MDT could preclude therapies supported by high-quality evidence, the choice of the best systemic treatment should precede MDT. Conclusion The increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Chemotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hormone therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cytoreductive prostatectomy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Metastasis-directed therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Slusarczyk, Aleksander</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quhal, Fahad</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klemm, Jakob</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matsukawa, Akihiro</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Przydacz, Mikołaj</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bryniarski, Piotr</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shariat, Shahrokh F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rajwa, Paweł</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Magazine of European Medical Oncology</subfield><subfield code="d">Wien : Springer, 2008</subfield><subfield code="g">17(2023), 1 vom: 18. Dez., Seite 35-39</subfield><subfield code="w">(DE-627)568488733</subfield><subfield code="w">(DE-600)2428960-7</subfield><subfield code="x">1865-5076</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:17</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:1</subfield><subfield code="g">day:18</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:35-39</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s12254-023-00938-6</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">17</subfield><subfield code="j">2023</subfield><subfield code="e">1</subfield><subfield code="b">18</subfield><subfield code="c">12</subfield><subfield code="h">35-39</subfield></datafield></record></collection>
|
| score |
7.401038 |